NEW YORK AND LONDON
Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, announced today the closing of its previously announced public offering of 1,533,333 American Depository Shares (ADSs) on the NASDAQ Capital Market at a price of $6.00 per ADS.